Becton Dickinson Other Non-Current Liabilities 2010-2024 | BDX

Becton Dickinson other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Becton Dickinson other non-current liabilities for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Becton Dickinson other non-current liabilities for 2023 were $0B, a NAN% decline from 2022.
  • Becton Dickinson other non-current liabilities for 2022 were $0B, a NAN% decline from 2021.
  • Becton Dickinson other non-current liabilities for 2021 were $0B, a NAN% decline from 2020.
Becton Dickinson Annual Other Non-Current Liabilities
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Becton Dickinson Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $65.165B $20.178B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $79.753B 21.76
Cardinal Health (CAH) United States $29.869B 16.20
West Pharmaceutical Services (WST) United States $23.239B 47.47
Labcorp (LH) United States $20.088B 16.66
Cooper (COO) United States $19.898B 28.32
Align Technology (ALGN) United States $17.037B 32.60
Henry Schein (HSIC) United States $9.198B 17.52
Merit Medical Systems (MMSI) United States $6.121B 31.26
DENTSPLY SIRONA (XRAY) United States $3.705B 10.08
CONMED (CNMD) United States $2.215B 18.48
Patterson (PDCO) United States $1.788B 9.43
STAAR Surgical (STAA) United States $1.312B 48.42
Lifevantage (LFVN) United States $0.165B 21.93
Pro-Dex (PDEX) United States $0.138B 27.49